

Potential therapeutic target for Huntington's disease

August 16 2016



A montage of three images of single striatal neurons transfected with a disease-associated version of huntingtin, the protein that causes Huntington's disease. Nuclei of untransfected neurons are seen in the background (blue). The neuron in the center (yellow) contains an abnormal intracellular accumulation of huntingtin called an inclusion body (orange). Credit: Wikipedia/ Creative

Commons Attribution 3.0 Unported license

There is new hope in the fight against Huntington's disease. Scientists at the Gladstone Institutes discovered that changing a specific part of the huntingtin protein prevented the loss of critical brain cells and protected against behavioral symptoms in a mouse model of the disease.

Huntington's disease causes jerky, uncoordinated movements and a loss of control of motor function. It also results in deficits in learning and memory, as well as personality changes, such as dementia, depression, and aggression. Huntington's is ultimately fatal, and there are no treatments to stop or slow its progression.

The disease is linked to a mutation in the Huntingtin gene, which causes a [protein](#) of the same name to fold up incorrectly like misshapen origami. Neurons cannot get rid of the misfolded protein, so it builds up in the brain, wreaking havoc in the cells.

In the new study, published in the *Journal of Clinical Investigation*, scientists in the laboratory of Steve Finkbeiner, MD, PhD, showed that modifying the [huntingtin protein](#) through a process called phosphorylation can actually make the protein less toxic and allows cells to eliminate it more easily. In fact, phosphorylating a specific spot on the protein called S421 protected a [mouse model](#) of Huntington's from developing symptoms of the disease.

"I was shocked at the profound effect phosphorylation had on the Huntington's model mice," said first author Ian Kratter, MD, PhD, a former graduate student at Gladstone and the University of California, San Francisco (UCSF). "They showed few signs of the motor dysfunction, depression, or anxiety that are characteristic of the disease.

In most of our tests, they were virtually indistinguishable from healthy mice."

The mice were also protected against neuron death, particularly in the striatum, the movement and reward center of the brain that is first affected in Huntington's disease. The scientists think that phosphorylation enables neurons to remove more of the harmful protein so it does not accumulate and damage the cell.

"Phosphorylation helps control how proteins fold and the systems in cells that clear proteins," explained Finkbeiner, who is a senior investigator at Gladstone. "This is exciting, because a lot of the work we've done points to these protein removal pathways as being important not only for Huntington's disease, but also for other neurodegenerative disorders. Understanding how phosphorylation links to these pathways could help treat several different brain diseases."

The researchers are now exploring ways to mimic the effects of phosphorylation with a drug.

More information: Ian H. Kratter et al. Serine 421 regulates mutant huntingtin toxicity and clearance in mice, *Journal of Clinical Investigation* (2016). [DOI: 10.1172/JCI80339](https://doi.org/10.1172/JCI80339)

Provided by Gladstone Institutes

Citation: Potential therapeutic target for Huntington's disease (2016, August 16) retrieved 11 May 2023 from <https://medicalxpress.com/news/2016-08-potential-therapeutic-huntington-disease.html>

This document is subject to copyright. Apart from any fair dealing for the purpose of private

study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.